Navidea Biopharmaceuticals Inc (NAVB) Upgraded to "Buy" by Zacks Investment Research

Navidea Biopharmaceuticals Inc (NAVB) Upgraded to "Buy" by Zacks Investment Research


The firm presently has a $1.25 price objective on the biopharmaceutical company's stock. Zacks Investment Research 's price target suggests a potential upside of 9.65% from the company's previous close.



from Biotech News